Neil D. Gross, MD, FACS
@DrNeilGrossProfessor & Director of Clinical Research, Head & Neck Surgery. Expert in cutaneous SCC, transoral robotic surgery (TORS). Proud father and outdoor enthusiast.
Similar User
@AHNSinfo
@RobertFerrisMD
@RajasekaranMD
@jpzevallos
@DrJohndeAlmeida
@EbenRosenthal
@DrGregFarwell
@DrShirleySu
@duvvuri_md
@VanderbiltENT
@DrHaddadRobert
@TopfHNS
@DrUppaluri
@HNSurgeon
@nicholslab1
Latest 🗞️on #neoadjuvant #immunotherapy for advanced, resectable @SquamousCscc #skin #cancer presented last week @myESMO #ESMO2024 showing durable improved survival at 29.4 months 📊#oncsurgery @MDAndersonNews Excited to launch #HN014 @NRGonc @TROGfightcancer 🔜
Neoadjuvant nivolumab & relatlimab in locally advanced MSI CRC @NatureMedicine doi.org/10.1038/s41591… 🔎NICHE-3 phs 2 👉PR 97%, MPR 92%, pCR 68% 👉only one recurrence 👉Gr 3–4 irAEs 10% 💪Impressive, we need to find the most effective, least toxic combination @myESMO
Final results of NRG HN004 coming out in Lancet Oncology, press release to follow, RT/cetux results look relatively strong for cisplatin ineligible HNSCC authors.elsevier.com/sd/article/S14…
🤦🏻♂️
These results likely represent surgeon preference, rather than impact of technique (TLM v. TORS), as many TORS surgeons use a prophylactic NG tube strategy.
Definitely some differences in selection of patients for TLM vs TORS, but these are not enough to explain the absolute increase of ~40% in NG tube requirements!
The #PATHOS team should be congratulated for completing a monumental phase 3 trial in #HPV #headandneck #cancer! Eager to see results as the data mature. Unusual to see secondary analyses ahead of primary, particularly with functional co-primary endpoint of MDADI. 🤔@EORTC
Wow...TLM for the win over TORS in PATHOS. - better MDADI scores (4.9 points overall, 10 points global, 6 points physical) - 2-day shorter hospital stays - fewer NG tubes (8% vs 45%) Life-threatening bleed 1% w/ TLM, 1.6% w/ TORS.
Thanks for the interest @SprakerMDPhD #HN014 is set to activate next month!The current SOC for advanced, resectable @SquamousCscc #skin #cancer is surgery and radiation. Indications for adjuvant radiation are standardized across both arms. @sueyom @NRGonc @NCICancerCtrl
Cool trial and good paper! What is your current standard for the phase 3 trial? If surgery, either arm allow adjuvant radiation? Would love more info!
Pathological response following neoadjuvant immune checkpoint inhibitors in HCC: a cross-trial, patient-level analysis @TheLancetOncol doi.org/10.1016/S1470-… 👉111 pts, 1.4 mo neoadj. 💊 👉MPR: 32%, PCR 18% 👉Best threshold 90% 🧐Neoadj ICI is the way to go @ILCAnews @EASLedu…
“Immunosuppressed patients with lower-risk cutaneous squamous cell carcinoma (cSCC) who score higher on the 40-gene expression profile (40-GEP) biomarker test are at greater risk of recurrence” #ASTRO24 #CleClinicCancer cle.clinic/3NcKWNK
Today in @JCO_ASCO: Final results of ORATOR, after completion of the full follow-up period. ascopubs.org/doi/10.1200/JC… We really need to rely on RCTs to compare treatments, and this trial will help people make informed decisions about their options.
Thanks for featuring our story on NFX-179 and chemoprevention of cutaneous SCC, @DrugDiscovNews @sarinkavita pubmed.ncbi.nlm.nih.gov/37820007/ drugdiscoverynews.com/a-new-gel-to-p…
Great to be at #SkinCancer2024 in Brisbane with soon-to-be @NRGonc #HN014 collaborators @drsydneychng @DrRahulLadwa @GuptaRuta #neoadjuvant #immunotherapy @SquamousCscc @AusSSC @sueyom
And Dr Kuruvilla shows that weekly is associated with less tinnitus or hearing impairment compared to 3-weekly… one more reason to move to weekly cisplatin! #ESMO2024
Scheduled for presentation soon @myESMO #ESMO2024 🗞️ Updated survival and new biomarker analyses from the phase 2 trial of #neoadjuvant #immunotherapy in resectable #squamous #skin #cancer #cSCC @SquamousCscc #hncsm @AHNSinfo @NRGonc @TROGfightcancer @Regeneron @MDAndersonNews
Time flies! Thank you 🙏 @MDAndersonNews for giving me the opportunity to continue to put patients first and help make #headandneck and #skin #cancer @SquamousCscc history. #hncsm #EndCancer #oncsurgery
Super great time seeing friends who are now collaborators at the always friendly, always stimulating @ANZHNCS meeting. Thank you @TROGfightcancer for your 35 years of service to cancer trials and the exciting partnership with @NRGonc !
International collaborations are pivotal for advancing science and bringing innovate therapies to patients who need the most. Thank you @sundap15 @sueyom @TROGfightcancer @JulieMcCrossin @LadwaRahul @anzhncs @NRGonc
Surprising results, stereotactic radiation plus anti-PD1 for stage 1-2 NSCLC, addition of immunotherapy does not confer benefit #lcsm merck.com/news/merck-pro…
United States Trends
- 1. #Arcane 214 B posts
- 2. Jake Paul 1,04 Mn posts
- 3. Jayce 44,9 B posts
- 4. #SaturdayVibes 2.653 posts
- 5. Serrano 246 B posts
- 6. Vander 14,4 B posts
- 7. Good Saturday 23,3 B posts
- 8. #HappySpecialStage 85,7 B posts
- 9. maddie 18,8 B posts
- 10. #saturdaymorning 1.871 posts
- 11. Jinx 100 B posts
- 12. #SaturdayMood 1.233 posts
- 13. Isha 33,8 B posts
- 14. Canelo 17,6 B posts
- 15. Father Time 10,8 B posts
- 16. Rizwan 8.045 posts
- 17. Woop Woop 1.259 posts
- 18. Super Tuna 22,1 B posts
- 19. The Astronaut 29,9 B posts
- 20. Logan 79,7 B posts
Who to follow
-
AHNS
@AHNSinfo -
Robert Ferris, MD, PhD
@RobertFerrisMD -
Karthik Rajasekaran
@RajasekaranMD -
José P. Zevallos, MD, MPH, FACS
@jpzevallos -
John De Almeida
@DrJohndeAlmeida -
Eben L Rosenthal, MD
@EbenRosenthal -
Dr Greg Farwell
@DrGregFarwell -
Dr Shirley Su
@DrShirleySu -
Umamaheswar Duvvuri MD PhD
@duvvuri_md -
VUMC Otolaryngology–Head and Neck Surgery
@VanderbiltENT -
Robert Haddad
@DrHaddadRobert -
Michael Topf MD, MSCI
@TopfHNS -
Ravi Uppaluri, MDPhD
@DrUppaluri -
Dr. Chris Holsinger
@HNSurgeon -
#nicholslab
@nicholslab1
Something went wrong.
Something went wrong.